Caidya is a full-service clinical research organization with capabilities spanning regulatory strategy, medical affairs, clinical operations, data management, biometrics, pharmacovigilance, quality management and post-approval surveillance. The company touts a strategic footprint in 23 countries and regions and deep therapeutic expertise in oncology, hematology, rare and pediatric diseases. Caidya emphasizes white-glove services, an agile partnership model, and customized solutions to help biopharma sponsors conduct studies with greater efficiency. The company was launched through the merger of dMed and Clinipace in 2021 and positions itself to serve biopharma innovation across the Americas, Europe, and APAC. Caidya plans to use new capital to support continued organic expansion and to explore strategic acquisitions as part of its next phase of growth. The announced $165 million strategic growth investment signals external financial backing to accelerate that plan and expand its global operations.

Total raised

$165M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2025